Chronic Myelomonocytic Leukemia

In this video, Noah Merin, MD, PhD, discusses the results of a study into the use of timdarpacept for chronic myelomonocytic leukemia, presented at ESMO Congress.

In this video, Douglas Tremblay, MD, discusses the results of a study into a first-line treatment of chronic myelomonocytic leukemia presented at ESMO Congress 2024.

The addition of pevonedistat to azacitidine for first-line treatment of certain patients with blood cancers failed to extend EFS, according to topline data released by the agent’s manufacturer.

Pevonedistat plus azacitidine increased overall survival, event-free survival and response rates compared with azacytidine alone in higher-risk myelodysplastic syndromes and low-blast acute myeloid leukemia, according to data presented at ASCO.